Key facts
- It has raised $3.0M; the latest was Later Stage VC ($17.7M) in Jan 2025.
- Notable investors include Bpifrance, European Innovation Council, SPRIM Global Investments, Cancéropôle Lyon Auvergne Rhône-Alpes, L'Agence Nationale de la Recherche — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for ErVimmune
- ·The full record, as it builds
Funding rounds
No funding rounds for ErVimmune are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About ErVimmune
Developer of a biotechnology company designed for immunotherapies targeting cold tumors that are unresponsive to current treatments. The company focuses on next-generation cancer vaccines and cell therapies, leveraging a newly identified class of tumor antigens- Human Endogenous Retroviruses, which are shared across tumors and patients, enabling patients to access cancer vaccines.
- Sector
- Healthcare
- HQ
- Lyon, France
- Founded
- 2019
- Employees
- 12
- Website
- ervimmune.com/
- Ownership
- Privately Held (backing)
ErVimmune doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in ErVimmune shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on ErVimmune in its N-PORT filings yet. We sweep new filings monthly.